Showing results (561-570 of 576) with videos related to

Sort By:
Pageof 58
The Journal of Antimicrobial Chemotherapy|May 16, 2021
Combination versus monotherapy as definitive treatment for Pseudomonas aeruginosa bacteraemia: a multicentre retrospective observational cohort studyTanya Babich, Pontus Naucler, John Karlsson Valik, et al.
International Journal of Antimicrobial Agents|November 27, 2019
Risk factors for mortality among patients with Pseudomonas aeruginosa bacteraemia: a retrospective multicentre studyTanya Babich, Pontus Naucler, John Karlsson Valik, et al.
Infectious Diseases and Therapy|May 25, 2022
Duration of Treatment for Pseudomonas aeruginosa Bacteremia: a Retrospective StudyTanya Babich, Pontus Naucler, John Karlsson Valik, et al.
The Lancet. Microbe|February 12, 2023
Global epidemiology and clinical outcomes of carbapenem-resistant Pseudomonas aeruginosa and associated carbapenemases (POP): a prospective cohort studyJinnethe Reyes, Lauren Komarow, Liang Chen, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 20, 2019
Ceftazidime, Carbapenems, or Piperacillin-tazobactam as Single Definitive Therapy for Pseudomonas aeruginosa Bloodstream Infection: A Multisite Retrospective StudyTanya Babich, Pontus Naucler, John Karlsson Valik, et al.
Infection|December 26, 2022
Outcomes of octogenarians and nonagenarians with Pseudomonas aeruginosa bacteremia: a multicenter retrospective studyAlaa Atamna, Ili Margalit, Gida Ayada, et al.
JAMA|February 12, 2020
Effect of Vancomycin or Daptomycin With vs Without an Antistaphylococcal β-Lactam on Mortality, Bacteremia, Relapse, or Treatment Failure in Patients With MRSA Bacteremia: A Randomized Clinical TrialSteven Y C Tong, David C Lye, Dafna Yahav, et al.
The Journal of Antimicrobial Chemotherapy|May 13, 2026
Emulating a target trial of early compared with late initiation of appropriate antibiotic therapy for hospital-acquired monobacterial Gram-negative bloodstream infectionsAbdullah T Aslan, Yukiko Ezure, Elif Seren Tanriverdi, et al.
The Lancet. Infectious Diseases|June 20, 2025
Olorofim for the treatment of invasive fungal diseases in patients with few or no therapeutic options: a single-arm, open-label, phase 2b studyJohan A Maertens, George R Thompson, Andrej Spec, et al.
Science Translational Medicine|September 14, 2022
A lipoglycopeptide antibiotic for Gram-positive biofilm-related infectionsMark A T Blaskovich, Karl A Hansford, Mark S Butler, et al.
Pageof 58